Form 4: Oncology Institute CEO Daniel Virnich Reports Acquisition and Disposal of Common Stock

Daniel Virnich, CEO of Oncology Institute, reports acquiring and disposing of common stock on March 31, 2025, according to a Form 4 filing.

Summary

• Daniel Virnich, the CEO of Oncology Institute, filed a Form 4 with the SEC.
• The filing reports a transaction on March 31, 2025, involving common stock.
• Virnich acquired 1,083,334 shares of common stock and disposed of an unspecified amount.
• Following the reported transaction, Virnich beneficially owns 1,807,697 shares of common stock.
• The acquisition of 1,083,334 shares was priced at $0.
• The shares were acquired through RSU (Restricted Stock Unit) awards that vest over four years, subject to continued service with the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock transactions by the CEO. The acquisition of shares could be seen as a positive, but it's part of a pre-determined RSU vesting schedule.

Positives

• The acquisition of shares by the CEO could be interpreted as a positive sign of confidence in the company's future.

Future Outlook

The vesting schedule of the RSU awards indicates a long-term commitment from the CEO to the company.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives.

Key Dates

Keywords

Form 4, Oncology Institute, Daniel Virnich, TOI, common stock, beneficial ownership, RSU, SEC filing